
The justices are set to hear Hikma v. Amarin, a battle over drug patents that could raise costs for patients and change the way generic companies do business. The United States pays undeniably high pr...
The justices are set to hear Hikma v. Amarin, a battle over drug patents that could raise costs for patients and change the way generic companies do business. The United States pays undeniably high pr...